BRISTOL MYERS SQUIBB

🇫🇷France

Country: 🇫🇷France

Ownership: -

Established: 1989-01-01

Employees: 30K

Market Cap: $97.5B

Website: https://www.bms.com/

Clinical Trials

Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer

Phase 2

Completed

Conditions: Colorectal Cancer (CRC)

Interventions: Drug: Irinotecan
Drug: 5-Fluorouracil (bolus)
Drug: 5-Fluorouracil (infusional)
Drug: Leucovorin calcium
Drug: CT-322
Drug: Bevacizumab
Drug: Bevacizumab Placebo (saline solution)

First Posted Date: 2009-02-25

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 17

Registration Number: NCT00851045

Locations: 🇺🇸
Midwest Center For Hematology/Oncology, Joliet, Illinois, United States
🇺🇸
Pharma Resource, East Providence, Rhode Island, United States
🇺🇸
Compassionate Cancer Care Medical Group Inc, Fountain Valley, California, United States

and more 10 locations

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Paclitaxel
Drug: Carboplatin
Drug: CT-322
Drug: Bevacizumab
Drug: Bevacizumab placebo (ie saline solution)

First Posted Date: 2009-02-25

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 255

Registration Number: NCT00850577

Locations: 🇺🇸
Palm Beach Cancer Institute, West Palm Beach, Florida, United States
🇺🇸
Clintell, Inc., Skokie, Illinois, United States
🇺🇸
North Canton Medical Clinic Center, Canton, Ohio, United States

and more 19 locations

An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism

Not Applicable

Completed

Conditions: Atherosclerosis

Interventions: Procedure: Blood draw

First Posted Date: 2009-02-19

Last Posted Date: 2009-11-05

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 150

Registration Number: NCT00847782

Locations: 🇨🇦
Local Institution, Montreal, Quebec, Canada

A Study of BMS-863233 in Patients With Hematologic Cancer

Phase 1

Terminated

Conditions: Refractory Hematologic Cancer

Interventions: Drug: Cdc7-inhibitor (BMS-863233)

First Posted Date: 2009-02-09

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 11

Registration Number: NCT00838890

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇺🇸
Roswell Park, Buffalo, New York, United States

and more 1 locations

Multiple-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of BMS-779788 in Healthy Subjects

Phase 1

Completed

Conditions: Atherosclerosis

Interventions: Drug: BMS-779788
Drug: Placebo

First Posted Date: 2009-02-04

Last Posted Date: 2011-02-23

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT00836602

Locations: 🇦🇺
Local Institution, Heidelberg, Victoria, Australia

Drug Interactions Between Voriconazole and Atazanavir Coadministered as Atazanavir/Ritonavir in Healthy Participants

Phase 1

Completed

Conditions: Human Immunodeficiency Virus Type 1 (HIV-1)
HIV Infections

Interventions: Drug: Voriconazole
Drug: Atazanavir
Drug: Ritonavir

First Posted Date: 2009-02-02

Last Posted Date: 2012-10-25

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 185

Registration Number: NCT00833482

Locations: 🇺🇸
West Coast Clinical Trials, Llc, Cypress, California, United States
🇳🇱
Local Institution, Nijmegen, Netherlands

Phase III Acute Coronary Syndrome

Phase 3

Terminated

Conditions: Acute Coronary Syndrome

Interventions: Drug: Placebo
Drug: Apixaban

First Posted Date: 2009-01-29

Last Posted Date: 2016-01-27

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 7484

Registration Number: NCT00831441

Locations: 🇺🇸
Central Jersey Medical Research Center, Elizabeth, New Jersey, United States
🇺🇸
Delmarva Heart Research Foundation, Salisbury, Maryland, United States
🇺🇸
Washington University School Of Medicine, St. Louis, Missouri, United States

and more 203 locations

Safety Study of Multiple-dose of Gamma-secretase Inhibitor in Healthy Male Japanese and Healthy Elderly Japanese

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: BMS-708163
Drug: Placebo

First Posted Date: 2009-01-26

Last Posted Date: 2011-01-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 32

Registration Number: NCT00828646

Locations: 🇯🇵
Local Institution, Yokohama, Kanagawa, Japan

Comparison of Brivanib and Best Supportive Care to Placebo for Treatment of Liver Cancer for Those Subjects Who Have Failed Sorafenib Treatment

Phase 3

Completed

Conditions: Liver Cancer

Interventions: Other: Placebo
Drug: Brivanib
Procedure: Best Supportive Care

First Posted Date: 2009-01-21

Last Posted Date: 2019-10-09

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 587

Registration Number: NCT00825955

Locations: 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
🇺🇸
UF Health Clinical Research Center, Gainesville, Florida, United States
🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

and more 17 locations

A Phase II, Multicenter, Double Blind, Placebo-Controlled Safety, Tolerability Study of BMS-708163 in Patients With Mild to Moderate Alzheimer's Disease

Phase 2

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: BMS-708163
Drug: Placebo

First Posted Date: 2008-12-17

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 209

Registration Number: NCT00810147

Locations: 🇺🇸
Yale University School Of Medicine, New Haven, Connecticut, United States
🇺🇸
Global Medical Institutes, Llc, Princeton, New Jersey, United States
🇺🇸
University Of Rochester, Rochester, New York, United States

and more 33 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy